Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
